The 2023-2028 World Outlook for Drug Discovery Outsourcing

The 2023-2028 World Outlook for Drug Discovery Outsourcing

This study covers the world outlook for drug discovery outsourcing across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

In this report we define the sales of drug discovery outsourcing as including all commonly understood products and/or services falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include Acurian, Advion Bioanalytical Labs, Albany MOLECULAR RESEARCH, Alexion, Almirall, SA, Antengene Corporation, Anthem Bio Science, Apredica, Aptuit, Argenta, Ark Therapeutics, Asclepia, Astex, AstraZeneca, Aurigene Discovery Technologies, Aurora Fine Chemicals, Auspherix, AutoGenomics, Awridian, Bayer, Behrman Capital, Bio Pontis Alliance, Bioduro, BioFocus, BioVersys, Boehringer Ingelheim, Brains On-Line, Bristol Myers Squibb, Bruker Daltonics, C4XDiscovery, Caprion Proteomics, Carna Biosciences, CAS, Celgene Corporation, CENTOGENE, ChanTest, Charles River, CHDI, Chiesi Farmaceutici, Chiltern International Group, Ltd., Chronos Therapeutics, CISYS Lifesciences, Covance, CRELUX, Cresset Discovery Services, CRL, Cyprotex, Daiichi Sankyo, Dalton Pharma Services, DaVita Clinical Research, DiscoveRx, Domainex, Domainnex., Dotmatics, Drug Discovery Alliances, Inc., Eisai Company, Elan, Eli Lilly and Company, EMBL, Enamine, ERT, Eurofins Scientific, Evidera, Evotec, Exquiron Biotech, Exscientia, Forma Therapeutics, Frenova Renal Research, Galapagos, General Electric Company, GenScript, Gilead Sciences, Inc., Great Lakes Chemical, Hangzhou Tigermed Consulting, Haplogen GmbH, HD Biosciences, HealthCore, Inc., Hellman & Friedman, HighRes Biosolutions, Horizon, Hypha Discovery, ICON, iGEM, Imperial College London, InSphero, Janssen Pharmaceuticals, Johnson & Johnson, JOINN Laboratories, Jubilant Biosys, Kellogg Company, Knopp Biosciences, KWS BioTest, LabCorp, LAURUS Labs, Lonza Group, Mayo Clinic, MedImmune, Merck & Company, Microbiologics, Midwest Bio Research, Moderna Therapeutics, Molecular Sensing, Inc., MPI Research, Nimbus Therapeutics, NovaLead Pharma Pvt, Ltd., Novo Nordisk, Oncodesign, Ono Pharmaceutical Company, ORIG3N, Inc., Paraxel, PathoQuest, Pelago Bioscience, Petra Pharma Corporation, Pharma Nest's Genesis, Pharmidex, Piramal Group, PPD, PRA International, Proteros biostructures, Qiagen, QuintilesIMS, Quotient Sciences, Rahme Lab, Regulus Therapeutics, ResearchPoint Global (RPG), Ricerca Biosciences LLC’s, Roche, Rules-Based Medicines, SAMDI Tech, Inc., Sanofi, SARomics Biostructures, Sciformix Corporation, Selcia, Ltd., Selvita, SenzaGen, Shang Pharma Corporation, Sharp Edge Labs, Inc., Shin Nippon Biomedical Laboratories, Shionogi, Siena Biotech, Sigma-Aldrich, Signature Discovery, Sirius Analytical, Solvo Biotechnology, SRI International, STA Pharmaceutical Company, Ltd., Syngene, Synthesis MedChem, Tesaro, TGS Lifesciences Pvt, Ltd., The Carlyle Group L.P. (Albany Molecular Research Inc.), UCB Pharma, Viva Biotech, Vivo Path, West Lafayette, WIL Research, WuXi App TecCo., X-Chem, and XtalPi. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2022).